Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Blood

Volumn 119, Issue 22, 2012, Pages 5126-5132

  Salles, Gilles ^a   Morschhauser, Franck ^b   Lamy, Thierry ^c   Milpied, Noel ^d   Thieblemont, Catherine ^e   Tilly, Hervé ^f   Bieska, Gabi ^g   Asikanius, Elina ^g   Carlile, David ^h   Birkett, Joe ^h   Pisa, Pavel ^g   Cartron, Guillaume ⁱ  

^a UNIVERSITÉ LYON 1   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ DE ROUEN   (France)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OBINUTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CANCER RELAPSE; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; IMMUNOLOGICAL PARAMETERS; INFECTION; INFUSION RELATED REACTION; INSOMNIA; ISCHIALGIA; LARYNX DISORDER; LARYNX IRRITATION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING; WEIGHT REDUCTION;

EID: 84861835530     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-404368     Document Type: Article

References (23)

1. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
2. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732.
3. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008; 112(13):4824-4831.
4. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/ resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28(17):2853-2858.
5. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
7. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab- CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12):2040-2045.
8. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837.
9. Chan HT, Hughes D, French RR, et al. CD20- induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489.
10. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738-2743.
11. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519- 4529.
12. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20): 3346-3353.
13. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/ refractory follicular lymphoma. Ann Oncol. 2010;21(9):1870-1876.
14. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495.
15. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22): 4393-4402.
16. Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152(3):295-306.
17. Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther. 2011;10(1):178-185.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-1253.
19. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15(10):3266-3274.
20. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217-2224.
21. Kimby E. Tolerability and safety of rituximab (Mab- Thera). Cancer Treat Rev. 2005;31(6):456-473.
22. Meneses-Lorente G, Carlile D, Birkett J, et al. Pharmacokinetics of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease (phase I/II study BO20999) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):1833.
23. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758.